EUCOPE Position Paper on Gene & Cell Therapies

Gene & Cell therapies have arrived, and bring with them important challenges.

Our paper proposes avenues to find solutions on:

  • HTA and evidential options;
  • Funding mechanisms;
  • Patient access and cross-border healthcare.

Upcoming Meetings

Regulatory WG, Brussels, 16 January (TC)

OMP WG, Brussels, 6 February

Gene & Cell Therapies TF, Brussels, 11 February

Members’ Meeting, Brussels, 26 February

Calendar

EUCOPE Membership

The content of the member area is exclusively available for members of EUCOPE.

To learn more about the advantages of the EUCOPE membership please contact us.

Contact us or Login

EUCOPE – the European Confederation of Pharmaceutical Entrepreneurs

EUCOPE is Europe’s principal trade body for small to medium-sized innovative companies working in the field of pharmaceuticals, biotechnologies and medical technologies.

Based in Brussels, Belgium, EUCOPE gives voice to more than 100 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.

As an industry stakeholder recognised by the European Institutions (EMA, European Commission, European Parliament and Council) and by national authorities, EUCOPE is following important EU and national legislative dossiers in market access, rare diseases, pharmacovigilance, and medical devices, with a speficic focus on the incentives framework.

Together with our members, we work to ensure an effective framework is in place to allow small to medium-sized pharmaceutical companies to continue to provide innovative solutions for patients in Europe.